Global Myomectomy Market - 2020-2027
|肌切開術的全球市場：2020-2027 Global Myomectomy Market - 2020-2027|
|出版日期: 按訂單生產||內容資訊: 英文||
Myomectomy is a surgical procedure to remove the uterine fibroids. These common non-cancerous growths in the uterus of women at their childbearing age, causing symptoms such as heavy bleeding during the menstrual cycle, increased menstrual cramping, pain in the pelvis or lower back, and swelling enlargement of the abdomen. Myomectomy differs from a hysterectomy. During myomectomy, the surgeons remove only the fibroids in the uterus, however, in a hysterectomy entire uterus is removed. Myomectomy preserves the chances of women getting pregnant. There are four types of myomectomy, including laparoscopic, abdominal, hysteroscopic, and robotic. The results of myomectomy are observed to be better, and women report improvement in fibroid symptoms, such as pelvic pressure and heavy menstrual bleeding.
The global myomectomy market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
The global myomectomy market growth is majorly driven by the rising prevalence of uterine fibroids and growing demand for diagnosis and treatment of the uterine disorder.
Uterine fibroids are the most common pelvic tumours in women, occurring globally with a prevalence of 21.4%. About 20% to 80% of women develop fibroids by the time they reach age 50. Fibroids are common in women in their 40s and early 50s. About 80% of African American women will develop fibroids by the age of 50. The increasing female ageing population is propelling the growth of the market as the elderly population are more susceptible to gynaecological problems, such as hormonal imbalance, abnormal uterine bleeding, and irregular menstrual cycle, which is fueling the demand of the global myomectomy market.
National Women's Health Network in the year 2015 reported that African-American women are two to three times more likely to develop fibroids than women of other races. According to the National Cancer Institute, 2015, there were an estimated 727,200 women living with uterine cancer in the United States, which supports the growth of the uterine fibroid treatment. In the United States, every year, approximately 6.5 million women seek treatment for fibroids and nearly 1/3 of employed patients (28%) report missing days of work due to fibroid symptoms.
Additionally, rising demand for medical devices for gynaecology procedures, increasing healthcare expenditure and overall growth of the healthcare industry also influences the market growth.
The growth of the medical device industry and the growing demand for technological advanced medical devices also boosts the growth of the market globally.
However, the growth of the myomectomy market is hampered due to high competition among players, complications associated with myomectomy, and high costs of devices. Myomectomy is associated with hemorrhage, infection, bowel obstruction, adhesion formation, damage to bowel, bladder, fallopian tube, ureter, wound infection and wound separation. About 20-25% of patients undergoing myomectomy require another pelvic operation, usually hysterectomy because of recurrence of symptoms. Recurrent myomas are common, especially in patients with multiple myomas. Patients with a solitary myoma have a 27% recurrence rate, and those with multiple myomas have a rate of 59%. Patients undergoing myomectomy should be counselled pre-operatively about these risks and must understand that myomectomy may not be possible.
The global myomectomy market is segmented by type, product, and end user.
There are four different ways to perform a myomectomy, including, hysteroscopic, laparoscopic, abdominal, and robotic. The procedures are minimally invasive and are considered permanent. If there are few fibroids, the laparoscopic or robotic procedure is opted, which uses slender instruments inserted through small incisions in the abdomen to remove the fibroids from the uterus. Larger fibroids are removed through smaller incisions by breaking them into pieces (morcellation), which can be done inside a surgical bag, or by extending one incision to remove the fibroids.
Robotic myomectomy gives a magnified, 3D view of the uterus, offering more precision, flexibility and dexterity than is possible using some other techniques. In October 2019, Sidra Medicine launched a fibroid removal programme using minimally invasive methods and robotic surgery. The Sidra Fibroid Centre is a new clinical multidisciplinary service launched by the Department of Gynaecology. Since opening its main hospital in January 2018, Sidra Medicine has proven itself as a pioneer in its field by using the latest technology and techniques to provide the highest levels of healthcare for the people of Qatar. It is also one of the only women's hospitals in the region to offer ground-breaking Robotic Myomectomy, a minimally invasive technique using robotic machines to remove uterine fibroids.
A hysteroscopic myomectomy is an option if the fibroids are contained inside the uterus (submucosal). The surgeon accesses and removes fibroids using instruments inserted through the vagina and cervix into the uterus. MyoSure by Hologic received CE Mark in Europe, MyoSure system is a minimally invasive hysteroscopic treatment option that is quick and convenient removal of tissue, which includes a range of fibroids and polys.
By product, the market is segmented into laparoscopic power morcellators, laparoscopic sealer, harmonic scalpel, and others. A power morcellator is a surgical instrument which is used in less-invasive abdominal procedures such as laparoscopic hysterectomies and fibroid removal. The U.S. Food and Drug Administration (FDA) cleared the first electric morcellator for sale in 1991. The first laparoscopic morcellator was launched in the market in 1995. The FDA classified the device as a class II and allowed it on the market through the 510(k) process. Before the FDA warning, surgeons used power morcellators in around 60,000 hysterectomies and myomectomies each year. The FDA alerted public that laparoscopic morcellators may be responsible for spreading and upstaging undiagnosed uterine cancer. In 2017, the FDA reaffirmed its 2014 guidance for laparoscopic power morcellators. The FDA did not change its recommendations for clinicians or recommend a ban based on its findings. After the FDA initial warning, several hospitals banned the device, and some insurance companies stopped covering power morcellator hysterectomy and fibroid removal. Johnson & Johnson, one of the largest makers of morcellators, pulled its devices off the market.
On the basis of end-user, the market is segmented into hospitals & clinics, surgical centers, medical device companies, and others. The rising number of minimally invasive surgeries is leading to higher market share for the hospital segment. The most commonly used approach used to remove uterine fibroids is a laparoscopic approach: myoma enucleation is done in procedures with organ preservation. The surgical procedures for uterine fibroids were about as common in the hospital-based ambulatory surgery (AS) setting as in the inpatient setting (47.8% vs. 52.2%). Compared with inpatient stays, AS visits had a shorter average length of stay (0.6 vs. 2.3 days) and lower average hospital charges ($25,200 vs. $28,000).
North America region is dominating the global myomectomy market accounting for the largest market share in 2019, owing to the rising prevalence of uterine disorders in the U.S., and increasing demand for new diagnostic and treatment services. Uterine fibroids affect about 40% of women between 30 to 55 years, including 20 million women in the North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.
The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at the age of 35, which increased to more than 80% by the age of 50 years among women.
Also, the adoption of minimally invasive and effective alternatives to open surgeries and technological advancements in devices with an increase in regulatory approvals and favourable reimbursement policies are expected to boost the growth of the myomectomy market in this region.
Europe is the second-largest market for myomectomy, due to rising demand for medical devices and availability of funds for research and development activities in the reproductive health. The growth of surgical devices in Germany, France, and the U.K also fuels the growth of the market. According to a study in Germany, the prevalence of uterine fibroids was detected in 41.6 % of all women. With increasing age, the prevalence of uterine fibroids rose from 21.3 % (30-35 years) to 62.8 % (46-50 years). The incidence of UFs in the UK was 5.8 per 1000 woman-years, as determined by the analysis of medical records. The rising incidences of uterine fibriods leads to growth in myomectomy market.
The myomectomy market is competitive and consists of several major players in the market. Some of the key players which are contributing to the growth of the market include Boston Scientific Corporation, Halt Medical, Inc., CooperSurgical Inc., F. Hoffmann-La Roche Ltd, KARL STORZ SE & Co. KG, Richard Wolf Medical Instruments, Siemens, Eli Lilly and Company, AbbVie Inc., Johnson & Johnson Services Inc., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the myomectomy market globally. For instance, in February 2020, Baxter International Inc., a leading global medical products company, has acquired the Seprafilm Adhesion Barrier and related assets from Sanofi for $350 million. The Seprafilm product family, which is used as an adjunct to reduce the incidence, extent and severity of adhesions in certain pelvic and abdominal surgeries, currently has a global commercial presence in the U.S., Japan, China, South Korea and France, among other countries.
The global myomectomy market report would provide an access to an approx. 61 market data table, 54 figures and 250 pages.
LIST NOT EXHAUSTIVE